arrow
B

Bali Pulendran

stanford medicine
H指数:104
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A comparative multiomic atlas of human immunity to multiple COVID-19 vaccines

人类对多种COVID-19疫苗免疫性的比较多组学图谱

2026-09-240
OAAI
Virus reactivation in acute and long COVID-19

急性期与长期新型冠状病毒肺炎中的病毒再激活

Nature
IF48.5
2026-08-050
OA
Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

经验性阿奇霉素改变了COVID-19患者上呼吸道微生物组和耐药组,但无抗炎益处。

2026-03-160
OAAI
Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors

作者更正:机器学习模型根据基线临床和免疫学因素预测长新冠结局

2026-02-230
OAAI
Mucosal vaccination in mice provides protection from diverse respiratory threats

张, H.; Floyd, K.; 方, Z.; Hoffmann, F.A.; Lee, A.; Froggatt, H.M.; Bharj, G.; Xie, X.; Eppler, H.B.; Santagata, J.M.; 等. 小鼠黏膜疫苗接种可抵御多种呼吸道威胁。Science 2026, eaea1260. [Google Scholar] [CrossRef] [PubMed]

Science
IF45.8
2026-02-190
PRE
Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors

机器学习模型根据基线临床和免疫学因素预测长新冠结局。

2026-01-030
OAAI
A multiomics recovery factor predicts long COVID in the IMPACC study

多组学恢复因子预测IMPACC研究中的长期COVID

2025-11-030
OA
Drivers of differential antibody breadth in SARS-CoV-2 mRNA vaccination and infection

SARS-CoV-2 mRNA疫苗接种和感染中差异抗体宽度的驱动因素

2025-11-010
PRE
Dysregulated regulatory T cell response in immunosuppressed individuals is associated with increased inflammation in COVID-19 breakthrough infections

免疫抑制个体中调节异常的调节性T细胞反应与新型冠状病毒肺炎突破性感染中炎症增加有关

2025-11-010
PRE
Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice

计算设计的mRNA启动的蛋白质纳米颗粒免疫原在 mice 中诱导保护性抗体和T细胞应答

2025-10-150
PRE
Acute and persistent responses after H5N1 vaccination in humans

人类接种H5N1疫苗后的急性和持续性反应

2024-09-010
OAAI
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

种系靶向HIV疫苗可诱导CD4结合位点的中和抗体

2024-08-301
PRE
Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses

掺入Toll样受体激动剂的皂苷纳米颗粒佐剂驱动不同的免疫特征和有效的疫苗反应

2024-08-091
OAAI